TRIUMPH-3: Phase 3 Weight Management in Cardiovascular Disease

Study Overview

TRIUMPH-3 evaluates retatrutide for weight management in adults with Class II/III obesity (BMI ≥35) and established cardiovascular disease (CVD). This trial enrolls participants both with and without type 2 diabetes, addressing a high-risk population where the intersection of severe obesity and cardiovascular disease creates significant morbidity and mortality.

Scientific Rationale

Obesity and Cardiovascular Risk

Class II/III obesity (BMI ≥35) is associated with substantially elevated cardiovascular risk, including higher rates of heart failure, coronary artery disease, stroke, and cardiovascular mortality. Weight reduction in this population has the potential to improve cardiovascular outcomes through multiple pathways: blood pressure reduction, improved lipid profiles, reduced systemic inflammation, and decreased cardiac workload.

Why This Population Matters

The overlap of severe obesity and established CVD represents one of the highest-risk subgroups in metabolic medicine. Semaglutide’s SELECT trial demonstrated cardiovascular benefit in overweight/obese patients with established CVD, setting a precedent for weight management therapies in this population. TRIUMPH-3 evaluates whether retatrutide’s greater weight loss magnitude and broader metabolic mechanism translate into meaningful benefit for these patients.

Study Design

TRIUMPH-3 is a randomized, double-blind, placebo-controlled, multicenter trial.

Participant Population

• Adults with Class II/III obesity (BMI ≥35 kg/m²)
• Established cardiovascular disease (e.g., prior myocardial infarction, stroke, or documented atherosclerotic disease)
• Enrollment includes patients with and without type 2 diabetes

Dose Selection

TRIUMPH-3 evaluates two dose levels:

• 9 mg once weekly
• 12 mg once weekly

The 4 mg dose is not included in this trial, reflecting the clinical rationale that patients with severe obesity and CVD are more likely to benefit from higher doses that maximize weight loss and metabolic improvement.

Endpoints

Primary endpoint:

• Percent change in body weight from baseline

Expected secondary endpoints:

• Proportion of participants achieving ≥5%, ≥10%, ≥15% weight loss thresholds
• Changes in cardiometabolic parameters (blood pressure, lipids, inflammatory markers)
• Changes in cardiac structure and function (echocardiographic substudy likely)
• HbA1c changes in participants with T2D
• Safety and tolerability, with particular attention to cardiovascular safety signals

Key Questions

1. Does retatrutide produce substantial weight loss in patients with severe obesity and established CVD — a population that is often harder to treat?
2. Are the cardiometabolic improvements (blood pressure, lipids, inflammation) observed in Phase 2 maintained in a cardiovascular disease population?
3. Is retatrutide safe and well-tolerated in patients with established CVD, who may have unique vulnerabilities to hemodynamic or metabolic perturbations?
4. How do the results compare between participants with and without concurrent type 2 diabetes?

Relationship to TRIUMPH-Outcomes

TRIUMPH-3 is a shorter-term efficacy trial focused on weight loss and cardiometabolic endpoints. It is distinct from TRIUMPH-Outcomes, which is the separate, large-scale (10,000-patient) cardiovascular outcomes trial (CVOT) designed to assess major adverse cardiovascular events (MACE) over a longer time horizon. TRIUMPH-3 contributes safety and efficacy data in the CVD population, while TRIUMPH-Outcomes provides the definitive cardiovascular event data needed for a potential CV risk reduction indication.

Significance

TRIUMPH-3 fills an important evidence gap by evaluating retatrutide in the specific population where obesity and cardiovascular disease intersect. Positive results would strengthen the case for retatrutide as a comprehensive cardiometabolic therapy and support regulatory submissions that include cardiovascular populations in the approved indication.